Nurix Therapeutics (NRIX) Depreciation & Amortization (CF) (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Depreciation & Amortization (CF) for 8 consecutive years, with $2.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) rose 0.58% year-over-year to $2.3 million; the TTM figure through May 2026 stood at $8.6 million (down 10.24% YoY), while the FY2025 annual figure was $8.7 million, down 6.63% from the prior year.
• Depreciation & Amortization (CF) climbed to $2.3 million in Q2 2026 per NRIX's latest filing, from $2.2 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.5 million in Q4 2024 and bottomed at $991000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $2.0 million across 5 years, with a median of $2.0 million in 2024.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 116.67% — and 2025, when it declined 18.4%.
• Nurix Therapeutics' Depreciation & Amortization (CF) stood at $1.6 million in 2022, then grew by 21.08% to $1.9 million in 2023, then soared by 34.09% to $2.5 million in 2024, then declined by 18.4% to $2.1 million in 2025, then advanced by 8.41% to $2.3 million in 2026.
• Business Quant data shows NRIX's Depreciation & Amortization (CF) at $2.3 million in Q2 2026, $2.2 million in Q1 2026, and $2.1 million in Q4 2025.